Paxillin regulates vascular endothelial growth factor A-induced in vitro angiogenesis of human umbilical vein endothelial cells

Yang,Wan‑Ju; Yang,Yan‑Ning; Cao,Jin; Man,Zi‑Hui; Li,Ying; Xing,Yi‑Qiao

doi:10.3892/mmr.2014.2961

Paxillin regulates vascular endothelial growth factor A-induced in vitro angiogenesis of human umbilical vein endothelial cells

Authors:
- Wan‑Ju Yang
- Yan‑Ning Yang
- Jin Cao
- Zi‑Hui Man
- Ying Li
- Yi‑Qiao Xing
View Affiliations

Affiliations: Eye Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: November 17, 2014 https://doi.org/10.3892/mmr.2014.2961
Pages: 1784-1792
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to investigate the role of paxillin in the vascular endothelial growth factor A (VEGF‑A)‑induced adhesion, proliferation, migration and capillary formation of endothelial cells (ECs) in vitro. Human umbilical vein ECs (HUVECs) were used to evaluate these four processes in vitro. The HUVECs were either mock‑transfected (control), transfected with scramble small interference RNA (siRNA) or transfected with siRNA specifically targeting paxillin. VEGF‑A (20 ng/ml) was used to stimulate angiogenesis. The VEGF‑A treatment significantly increased the adhesion, proliferation, migration and tube formation of the HUVECs in the control and scramble siRNA groups, whereas the siRNA‑mediated knockdown of paxillin inhibited these VEGF‑A‑induced effects. Paxillin is essential for VEGF‑A‑mediated angiogenesis in ECs and its inhibition may be a potential target for antiangiogenic therapies.

View Figures

View References

1	Chang JH, Gabison EE, Kato T and Azar DT: Corneal neovascularization. Curr Opin Ophthalmol. 12:242–249. 2001. View Article : Google Scholar : PubMed/NCBI
2	Regenfuss B, Bock F, Parthasarathy A and Cursiefen C: Corneal (lymph) angiogenesis - from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol. 6:191–201. 2008. View Article : Google Scholar
3	Chevez-Barrios P: Are we getting closer to prevention and treatment of corneal neovascularization? Clin Experiment Ophthalmol. 35:689–690. 2007. View Article : Google Scholar : PubMed/NCBI
4	Cursiefen C, Kuchle M and Naumann GO: Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea. 17:611–613. 1998. View Article : Google Scholar : PubMed/NCBI
5	Gupta D and Illingworth C: Treatments for corneal neovascularization: a Review. Cornea. 30:927–938. 2011. View Article : Google Scholar : PubMed/NCBI
6	Lim P, Fuchsluger TA and Jurkunas UV: Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol. 24:139–148. 2009. View Article : Google Scholar : PubMed/NCBI
7	Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 9:267–285. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ebrahem Q, Chaurasia SS, Vasanji A, et al: Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol. 176:496–503. 2010. View Article : Google Scholar :
9	Hoeben A, Landuyt B, Highley MS, et al: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
10	Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 39:469–478. 2006. View Article : Google Scholar : PubMed/NCBI
11	Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
12	Stefanini MO, Wu FT, Mac Gabhann F and Popel AS: The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. PLoS Comput Biol. 5:e10006222009. View Article : Google Scholar : PubMed/NCBI
13	Turner CE: Paxillin. Int J Biochem Cell Biol. 30:955–959. 1998. View Article : Google Scholar : PubMed/NCBI
14	Brown MC and Turner CE: Paxillin: adapting to change. Physiol Rev. 84:1315–1339. 2004. View Article : Google Scholar : PubMed/NCBI
15	Abedi H and Zachary I: Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem. 272:15442–15451. 1997. View Article : Google Scholar : PubMed/NCBI
16	Birukova AA, Cokic I, Moldobaeva N and Birukov KG: Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF. Am J Respir Cell Mol Biol. 40:99–107. 2009. View Article : Google Scholar :
17	Oh J, Diaz T, Wei B, et al: TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene. 25:4230–4234. 2006. View Article : Google Scholar : PubMed/NCBI
18	Petit V, Boyer B, Lentz D, et al: Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol. 148:957–970. 2000. View Article : Google Scholar : PubMed/NCBI
19	Rios A, Hernandez-Ramirez VI, Moguel M, et al: Participation of Rho, ROCK-2, and GAP activities during actin microfilament rearrangements in Entamoeba histolytica induced by fibronectin signaling. Cell Biol Int. 32:984–1000. 2008. View Article : Google Scholar : PubMed/NCBI
20	Tsubouchi A, Sakakura J, Yagi R, et al: Localized suppression of RhoA activity by Tyr31/118-phosphorylated paxillin in cell adhesion and migration. J Cell Biol. 159:673–683. 2002. View Article : Google Scholar : PubMed/NCBI
21	Dobkin-Bekman M, Naidich M, Rahamim L, et al: A preformed signaling complex mediates GnRH-activated ERK phosphorylation of paxillin and FAK at focal adhesions in L beta T2 gonadotrope cells. Mol Endocrinol. 23:1850–1864. 2009. View Article : Google Scholar : PubMed/NCBI
22	Sachdev S, Bu Y and Gelman IH: Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion. BMC Cancer. 9:122009. View Article : Google Scholar : PubMed/NCBI
23	Jaffe EA, Nachamann RL, Becker CG and Minick CR: Culture of human endothelial cells derived from umbilical cord veins. Identification by morphologic and immunologic criteria. J Clin Invest. 52:2745–2756. 1973. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Turner NA and Moake J: Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. Plos one. 8:e593722013. View Article : Google Scholar : PubMed/NCBI
26	Shan C, Xu F, Zhang S, et al: Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2. Cell Res. 20:563–575. 2010. View Article : Google Scholar : PubMed/NCBI
27	Ng YS, Krilleke D and Shima DT: VEGF function in vascular pathogenesis. Exp Cell Res. 312:527–537. 2006. View Article : Google Scholar
28	Tammela T, Enholm B, Alitalo K and Paavonen K: The biology of vascular endothelial growth factors. Cardiovasc Res. 65:550–563. 2005. View Article : Google Scholar : PubMed/NCBI
29	Van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al: A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol. 96:587–590. 2012. View Article : Google Scholar : PubMed/NCBI
30	Velez-Montoya R, Clapp C, Rivera JC, et al: Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity. Clin Ophthalmol. 4:947–953. 2010. View Article : Google Scholar : PubMed/NCBI
31	Ferrara N: Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med. 16:1107–1111. 2010. View Article : Google Scholar : PubMed/NCBI
32	Chen JY, Tang YA, Huang SM, et al: A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res. 71:473–483. 2011. View Article : Google Scholar : PubMed/NCBI
33	Yang YN, Wang F, Zhou W, Wu ZQ and Xing YQ: TNF-alpha stimulates MMP-2 and MMP-9 activities in human corneal epithelial cells via the activation of FAK/ERK signaling. Ophthalmic Res. 48:165–170. 2012. View Article : Google Scholar
34	Lee S, Zheng M, Kim B and Rouse BT: Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest. 110:1105–1111. 2002. View Article : Google Scholar : PubMed/NCBI
35	Bischoff J: Cell adhesion and angiogenesis. J Clin Invest. 100:S37–S39. 1997.PubMed/NCBI
36	Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:11–25. 1992. View Article : Google Scholar : PubMed/NCBI
37	Wary KK, Kohler EE and Chatterjee I: Focal adhesion kinase regulation of neovascularization. Microvasc Res. 83:64–70. 2012. View Article : Google Scholar
38	Teranishi S, Kimura K and Nishida T: Role of formation of an ERK-FAK-paxillin complex in migration of human corneal epithelial cells during wound closure in vitro. Invest Ophthalmol Vis Sci. 50:5646–5652. 2009. View Article : Google Scholar : PubMed/NCBI
39	Takahashi T, Yamaguchi S, Chida K and Shibuya M: A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 20:2768–2778. 2001. View Article : Google Scholar : PubMed/NCBI
40	Turner CE: Paxillin interactions. J Cell Sci. 113:4139–4140. 2000.PubMed/NCBI
41	Hagel M, George EL, Kim A, et al: The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling. Mol Cell Biol. 22:901–915. 2002. View Article : Google Scholar : PubMed/NCBI
42	Lai KM and Pawson T: The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo. Genes Dev. 14:1132–1145. 2000.PubMed/NCBI
43	Shaw LM, Rabinovitz I, Wang HH, Toker A and Mercurio AM: Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell. 91:949–960. 1997. View Article : Google Scholar
44	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI